Needham has downgraded Haemonetics Corp (HAE) from a Buy to a Hold rating as of December 14, 2025. This decision indicates a shift towards increased caution regarding the company's outlook. Analysts suggest that this revision may reflect concerns about competitive pressures, market conditions, or execution risks that could affect Haemonetics' performance.
Haemonetics, headquartered in Boston, Massachusetts, develops and distributes hematology products and solutions. With a market capitalisation of $4.0 billion, the company operates in the healthcare sector, employing 3,023 full-time staff. Its technology serves various medical markets, including blood and plasma component collection, surgical suites, and hospital transfusion services. The company’s Plasma segment encompasses plasma collection devices and software, while its Blood Center segment provides apheresis solutions for automated blood collection.
The current share price stands at $80.27, with a price-to-earnings ratio of 23.57 and earnings per share of 3.43. Looking ahead, Haemonetics is expected to report earnings on August 5, 2026, with an estimated EPS of $1.25 and revenue of $341.1 million.
Analyst ratings and price targets offer insights based on research and financial models. However, these assessments are based on assumptions that may not always materialise. Investors should consider multiple factors, including company fundamentals, competitive positioning, and industry trends, alongside analyst opinions when making decisions. Analyst ratings can change as new information becomes available, reflecting the evolving nature of market conditions.